SEC Form SC 13G filed by Blue Water Acquisition Corp.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.  )*

CLARUS THERAPEUTICS HOLDINGS, INC.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

18271L107

(CUSIP Number)

September 9, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

¹ Based upon 21,725,817 shares of common stock of the Issuer reported to be outstanding in the Issuer’s Form 8-K, filed with the SEC on September 15, 2021.

² Based upon 21,725,817 shares of common stock of the Issuer reported to be outstanding in the Issuer’s Form 8-K, filed with the SEC on September 15, 2021.

³ Based upon 21,725,817 shares of common stock of the Issuer reported to be outstanding in the Issuer’s Form 8-K, filed with the SEC on September 15, 2021.

⁴ Based upon 21,725,817 shares of common stock of the Issuer reported to be outstanding in the Issuer’s Form 8-K, filed with the SEC on September 15, 2021.

⁵ Based upon 21,725,817 shares of common stock of the Issuer reported to be outstanding in the Issuer’s Form 8-K, filed with the SEC on September 15, 2021.

CLARUS THERAPEUTICS HOLDINGS, INC. (the “Issuer”)

This Schedule 13G is filed by and on behalf of:

This statement on Schedule 13G relates to securities directly held by CBC SPVI Ltd.

CBC SPVI Ltd is wholly owned by C-Bridge Healthcare Fund, L.P., which is controlled by its general partner, C-Bridge Healthcare Fund GP, L.P., which is controlled by its general partner, C-Bridge Capital GP, Ltd., which, in turn, is controlled by Mr. Wei Fu, serving as its director.

C-Bridge Healthcare Fund, L.P., C-Bridge Healthcare Fund GP, L.P., C-Bridge Capital GP, Ltd., and Mr. Wei Fu may be deemed to beneficially own the securities of the Issuer owned by the entities which they control.

The business address of each reporting person is Suites 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

Common stock, par value $0.0001 per share

Not applicable.

The information for each reporting person contained in rows 5-11 of the cover pages and Item 2(a) is incorporated herein by reference.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 24, 2021

LIST OF EXHIBITS